Serological diagnostics of hepatitis B in clinical laboratories is mainly based on detection of HBs antigen (HBsAg) in human serum or plasma using commercial ELISA kits. In manufacturing and laboratory practice, sensitivity of ELISA kit is measured against either international or national reference standard. This approach is necessary, but limited as it does not take into account factors that influence on HBsAg detection kit potency at low HBsAg concentration and when HBsAg subtypes/variants are present in species. Several panels containing human HBsAg positive and HBsAg negative sera were prepared and then used for testing of commercial kits HBsAg detection efficacy either under the conditions of reference or clinical laboratories: (1) broadened panels containing 138 and 157 samples were used for lot-to-lot comparison of kits detecting HBsAg; (2) low titer panel containing 21 samples was used for the evaluation the detection limit of kits; (3) mini low titer HBsAg panels containing 17 samples were used for interlaboratory control in Moscow; (4) panel containing 38 diluted human sera (35 sera with "wild" type HBsAg and 3 abnormal sera with presumably mutant HBsAg) was used for the performance evaluation of kits. Variants of HBsAg were found in 11 sera among 132 HBsAg positive sera titrated in ELISA in the presence of monoclonal antibodies against a-determinant of HBsAg. For 4 of them the measured level of HBsAg varied 10-100 times with the change of the kit or type of monoclonal antibodies. The data obtained suggest that each control panel could be a useful tool for estimation of both the kit detection potency and laboratory assay efficacy.

Download full-text PDF

Source

Publication Analysis

Top Keywords

hbsag
17
clinical laboratories
8
hbsag detection
8
hbsag positive
8
low titer
8
monoclonal antibodies
8
kits
6
sera
6
detection
5
performance elisa
4

Similar Publications

Background: Hepatitis B virus infection is one of the major concerns in global health care. With a far-reaching health, social, economic impact, preventive strategies form the cornerstone of its management. Knowledge about vaccination status and protection rendered thereof would aid in more wholesome management among highrisk population groups like healthcare workers.

View Article and Find Full Text PDF

HBV and HCV testing outcomes among marginalized communities in Italy, 2019-2024: a prospective study.

Lancet Reg Health Eur

February 2025

Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Italy.

Background: The health of the marginalized populations is crucial for public health and inequalities. The World Health Organization (WHO) Global Hepatitis Report 2024 stated that over 304 million people were living with Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) infection in 2022. We performed HBV/HCV screenings among marginalized communities to reveal hidden infections and link-to-care positive participants.

View Article and Find Full Text PDF

[The distributions of serum HBsAg level in chronic hepatitis B patients based on the China Registry of Hepatitis B (CR-HepB)].

Zhonghua Gan Zang Bing Za Zhi

December 2024

Liver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center for Digestive Diseases, Beijing100050, China.

To determine the distributions of serum HBsAg level in treatment-naive or treatment-experienced chronic hepatitis B (CHB) patients. Based on the China Registry of Hepatitis B (CR-HepB), a nationwide hospital-based electronic platform, treatment-naive or treatment-experienced CHB patients who receive nucleos(t)ide analog (NA) therapy were enrolled in our study. We collected patients' clinical characteristics, including demographic, virological and biochemical data.

View Article and Find Full Text PDF

Background: Hepatitis B is a significant public health issue worldwide. Long noncoding RNAs (lncRNAs) are pivotal in biological mechanisms. The involvement of lncRNAs in hepatitis Hepatitis B remains incompletely understood.

View Article and Find Full Text PDF

No cost-effectiveness information of preventive strategies for mother-to-child transmission (MTCT) of hepatitis B virus (HBV) has existed for policy decision making. This study aimed to compare the cost-effectiveness of alternative strategies to prevent MTCT of HBV in Vietnam. Cost-utility analysis using a hybrid decision-tree and Markov model were performed from healthcare system and societal perspectives.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!